NASDAQ:IART - Integra Lifesciences Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $52.92 +0.40 (+0.76 %) (As of 11/15/2018 12:06 PM ET)Previous Close$52.52Today's Range$52.04 - $52.9252-Week Range$45.96 - $67.50Volume5,140 shsAverage Volume717,031 shsMarket Capitalization$4.60 billionP/E Ratio27.23Dividend YieldN/ABeta0.76 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. It offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. The company also sells approximately 60,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, it provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, the company sells hardware products, such as bone and joint fixation, and joint replacement devices; implants; and instruments, which provide for the orthopedic reconstruction of bone in the hand, wrist, elbow, and shoulder, as well as the foot, ankle, and leg below the knee in the extremity bone and joint reconstruction procedures. Integra LifeSciences Holdings Corporation offers its products directly through various sales forces and other distribution channels in the United States, Europe, and internationally. The company was founded in 1989 and is headquartered in Plainsboro, New Jersey. Receive IART News and Ratings via Email Sign-up to receive the latest news and ratings for IART and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:IART Previous Symbol CUSIP45798520 Webwww.integralife.com Phone609-275-0500 Debt Debt-to-Equity Ratio1.04 Current Ratio3.20 Quick Ratio2.08 Price-To-Earnings Trailing P/E Ratio27.23 Forward P/E Ratio22.14 P/E Growth1.68 Sales & Book Value Annual Sales$1.19 billion Price / Sales3.79 Cash Flow$3.0590 per share Price / Cash17.30 Book Value$16.03 per share Price / Book3.30 Profitability EPS (Most Recent Fiscal Year)$1.94 Net Income$64.74 million Net Margins5.49% Return on Equity16.99% Return on Assets6.18% Miscellaneous Employees4,400 Outstanding Shares85,180,000Market Cap$4.60 billion OptionableOptionable Integra Lifesciences (NASDAQ:IART) Frequently Asked Questions What is Integra Lifesciences' stock symbol? Integra Lifesciences trades on the NASDAQ under the ticker symbol "IART." When did Integra Lifesciences' stock split? How did Integra Lifesciences' stock split work? Integra Lifesciences shares split before market open on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly issued shares were payable to shareholders after the closing bell on Wednesday, December 21st 2016. An investor that had 100 shares of Integra Lifesciences stock prior to the split would have 200 shares after the split. How were Integra Lifesciences' earnings last quarter? Integra Lifesciences Holdings Corp (NASDAQ:IART) released its earnings results on Wednesday, October, 31st. The life sciences company reported $0.59 earnings per share for the quarter, meeting the Zacks' consensus estimate of $0.59. The life sciences company earned $365.85 million during the quarter, compared to the consensus estimate of $367.89 million. Integra Lifesciences had a return on equity of 16.99% and a net margin of 5.49%. Integra Lifesciences's revenue for the quarter was up 31.2% on a year-over-year basis. During the same period in the prior year, the business earned $0.45 earnings per share. View Integra Lifesciences' Earnings History. When is Integra Lifesciences' next earnings date? Integra Lifesciences is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Integra Lifesciences. What guidance has Integra Lifesciences issued on next quarter's earnings? Integra Lifesciences issued an update on its FY18 earnings guidance on Wednesday, October, 31st. The company provided earnings per share (EPS) guidance of $2.36-2.42 for the period, compared to the Thomson Reuters consensus estimate of $2.40. The company issued revenue guidance of $1.467-1.472 billion, compared to the consensus revenue estimate of $1.49 billion.Integra Lifesciences also updated its FY 2018 guidance to $2.36-2.42 EPS. What price target have analysts set for IART? 13 brokers have issued 12 month target prices for Integra Lifesciences' stock. Their predictions range from $53.00 to $70.00. On average, they anticipate Integra Lifesciences' share price to reach $61.2727 in the next year. This suggests a possible upside of 17.4% from the stock's current price. View Analyst Price Targets for Integra Lifesciences. What is the consensus analysts' recommendation for Integra Lifesciences? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Integra Lifesciences in the last year. There are currently 1 sell rating, 8 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Integra Lifesciences. What are Wall Street analysts saying about Integra Lifesciences stock? Here are some recent quotes from research analysts about Integra Lifesciences stock: 1. According to Zacks Investment Research, "Significant gross margin contractions caused by escalating costs have been a major headwind for Integra Lifesciences. Added to this, a tough competitive landscape adds to the company’s woes. Despite these hurdles, Integra Lifesciences has outperformed its industry over the past month. Solid growth across all business segments has been the key growth catalyst. Integra’s successful progress with its channel expansion strategy and Codman integration buoy optimism. Notably, the company announced plans within Orthopedics and Tissue Technologies segment to expand its sales channel, improve focus and competitiveness and better align the company’s product portfolio with clinical customers. Moreover, the strong investments in research and development is encouraging. The company’s promising guidance also instills confidence in the stock." (11/13/2018) 2. BTIG Research analysts commented, "We hosted investor meetings with mgmt. of IART which included President & CEO for multiple days of meetings in the Midwest. Investors were interested in understanding a variety of topics, including the Codman integration, wound, nerve, and dural repair market dynamics, OTT channel changes, as well as other areas of the business. We came away with a clearer picture of IART’s progression toward a higher growth company driven by sales force productivity improvements, product registrations OUS, and a growing pipeline from Codman (a previously underfunded asset). The Street may not be as focused on much of the back-office work that has taken place at IART over FY18 but mgmt. was confident in their ability to meet FY18 organic revenue growth guidance (~5%) and grow above that in FY19 and beyond. Our incremental takeaways are below." (10/11/2018) 3. Cantor Fitzgerald analysts commented, ": We maintain our Neutral rating and $59 12-month PT on shares of IART. This morning (7/25), IART reported 2Q rev of $366MM (+3.4% organic), slightly below consensus ($368MM). IART’s 3.4% organic growth was a slight sequential acceleration (+3.0% in 1Q18). (+33%) were in line, as a lower tax rate offset margin weakness relative to expectations. IART reiterated its 2018 top-line organic growth guidance of ~5%, implying 2H18 organic growth of 6.5%, twice that of 1H18." (7/25/2018) Has Integra Lifesciences been receiving favorable news coverage? News coverage about IART stock has been trending somewhat positive on Thursday, InfoTrie reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Integra Lifesciences earned a news impact score of 0.6 on InfoTrie's scale. They also gave news headlines about the life sciences company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days. Who are some of Integra Lifesciences' key competitors? Some companies that are related to Integra Lifesciences include ABIOMED (ABMD), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hill-Rom (HRC), Haemonetics (HAE), Globus Medical (GMED), Insulet (PODD), Penumbra (PEN), ICU Medical (ICUI), Cantel Medical (CMD), Merit Medical Systems (MMSI), NuVasive (NUVA), Novocure (NVCR) and Glaukos (GKOS). Who are Integra Lifesciences' key executives? Integra Lifesciences' management team includes the folowing people: Mr. Peter J. Arduini, Pres, CEO & Director (Age 53)Dr. Richard E. Caruso Ph.D., Founder and Chairman Emeritus (Age 75)Mr. Glenn G. Coleman, Corp. VP of International & CFO (Age 50)Mr. Richard D. Gorelick, Corp. VP of Admin., Gen. Counsel & Sec. (Age 57)Mr. Daniel L. Reuvers, Corp. VP and Pres of Specialty Surgical Solutions (Age 55) Who are Integra Lifesciences' major shareholders? Integra Lifesciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (13.68%), Capital Research Global Investors (11.96%), BlackRock Inc. (7.65%), Janus Henderson Group PLC (2.36%), Capital World Investors (1.33%) and Jennison Associates LLC (1.19%). Company insiders that own Integra Lifesciences stock include Barbara B Hill, Christian S Schade, Daniel L Reuvers, Donald E Morel Jr, Glenn Coleman, James M Sullivan, Jeffrey Mosebrook, Joseph Vinhais, Keith Bradley, Richard D Gorelick, Richard E Caruso and Stuart Essig. View Institutional Ownership Trends for Integra Lifesciences. Which major investors are selling Integra Lifesciences stock? IART stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Dimensional Fund Advisors LP, Tributary Capital Management LLC, SG Americas Securities LLC, Hsbc Holdings PLC, Martingale Asset Management L P, Comerica Bank and Fisher Asset Management LLC. Company insiders that have sold Integra Lifesciences company stock in the last year include Christian S Schade, Daniel L Reuvers, Glenn Coleman, Jeffrey Mosebrook, Joseph Vinhais, Keith Bradley, Richard E Caruso and Stuart Essig. View Insider Buying and Selling for Integra Lifesciences. Which major investors are buying Integra Lifesciences stock? IART stock was bought by a variety of institutional investors in the last quarter, including Capital World Investors, FMR LLC, Capital Research Global Investors, First Trust Advisors LP, Renaissance Technologies LLC, Deutsche Bank AG, JPMorgan Chase & Co. and JPMorgan Chase & Co.. Company insiders that have bought Integra Lifesciences stock in the last two years include Barbara B Hill and Donald E Morel Jr. View Insider Buying and Selling for Integra Lifesciences. How do I buy shares of Integra Lifesciences? Shares of IART can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Integra Lifesciences' stock price today? One share of IART stock can currently be purchased for approximately $52.18. How big of a company is Integra Lifesciences? Integra Lifesciences has a market capitalization of $4.60 billion and generates $1.19 billion in revenue each year. The life sciences company earns $64.74 million in net income (profit) each year or $1.94 on an earnings per share basis. Integra Lifesciences employs 4,400 workers across the globe. What is Integra Lifesciences' official website? The official website for Integra Lifesciences is http://www.integralife.com. How can I contact Integra Lifesciences? Integra Lifesciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The life sciences company can be reached via phone at 609-275-0500 or via email at [email protected] MarketBeat Community Rating for Integra Lifesciences (NASDAQ IART)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 350 (Vote Outperform)Underperform Votes: 384 (Vote Underperform)Total Votes: 734MarketBeat's community ratings are surveys of what our community members think about Integra Lifesciences and other stocks. Vote "Outperform" if you believe IART will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IART will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/15/2018 by MarketBeat.com StaffFeatured Article: What is Liquidity?